Editor's Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway.

MLA

Zauli, Giorgio, et al. “Editor’s Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both P53wild-Type and P53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 13, July 2022, p. 2972. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-22-1596.

APA

Zauli, G., Voltan, R., Bosco, R., Melloni, E., Marmiroli, S., Rigolin, G. M., Cuneo, A., & Secchiero, P. (2022). Editor’s Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 28(13), 2972. https://doi.org/10.1158/1078-0432.CCR-22-1596

Chicago

Zauli, Giorgio, Rebecca Voltan, Raffaella Bosco, Elisabetta Melloni, Sandra Marmiroli, Gian Matteo Rigolin, Antonio Cuneo, and Paola Secchiero. 2022. “Editor’s Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both P53wild-Type and P53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28 (13): 2972. doi:10.1158/1078-0432.CCR-22-1596.